Tradipitant effective in preventing motion sickness
Vanda Pharma announced that tradipitant, a neurokinin-1 receptor antagonist, was effective in treating motion sickness in a clinical study conducted in the Pacific Ocean. Vanda intends to initiate a Phase III program in Motion Sickness, with a plan to file for marketing authorization in 2020. July 16, 2019